Literature DB >> 2717522

Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa.

M Hu1, P Subramanian, H I Mosberg, G L Amidon.   

Abstract

Intestinal permeabilities of five dipeptidyl derivatives of L-alpha-methyldopa (I) were studied by an in situ intestinal perfusion method. The dipeptides displayed a significant increase in their permeabilities compared to L-alpha-methyldopa. The increases ranged from 4 to 20 times. These results suggest that the peptide transport system is less structurally specific than the amino acid transport systems and can be used as an absorption pathway for peptide analogues. The kinetic advantage demonstrated by the dipeptide, L-alpha-methyldopa-L-phenylalanine, over the amino acid analogue, L-alpha-methyldopa, suggests that the peptide carrier would be a possible route for improving the intestinal absorption of pharmacologically active amino acid analogues. Furthermore, the preliminary results of in vitro hydrolysis studies of selected dipeptidyl derivatives indicate that the peptide carrier system could be used as a base for a prodrug strategy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2717522     DOI: 10.1023/a:1015855820488

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  Pharmacokinetics of methyldopa in healthy man.

Authors:  O Stenbaek; E Myhre; H E Rugstad; E Arnold; T Hansen
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953

Review 2.  Is intestinal peptide transport energized by a proton gradient?

Authors:  F H Leibach
Journal:  Am J Physiol       Date:  1985-08

3.  The effect of pH and concentration on alpha-methyldopa absorption in man.

Authors:  A E Merfeld; A R Mlodozeniec; M A Cortese; J B Rhodes; J B Dressman; G L Admidon
Journal:  J Pharm Pharmacol       Date:  1986-11       Impact factor: 3.765

4.  Improved delivery through biological membranes. 4. Prodrugs of L-dopa.

Authors:  N Bodor; K B Sloan; T Higuchi; K Sasahara
Journal:  J Med Chem       Date:  1977-11       Impact factor: 7.446

5.  Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds.

Authors:  G L Amidon; P J Sinko; D Fleisher
Journal:  Pharm Res       Date:  1988-10       Impact factor: 4.200

6.  Synthesis and antihypertensive activity of some ester progenitors of methyldopa.

Authors:  W S Saari; M B Freedman; R D Hartman; S W King; A W Raab; W C Randall; E L Engelhardt; R Hirschmann; A Rosegay; C T Ludden; A Scriabine
Journal:  J Med Chem       Date:  1978-08       Impact factor: 7.446

7.  Membrane permeability parameters for some amino acids and beta-lactam antibiotics: application of the boundary layer approach.

Authors:  M Hu; P J Sinko; A L deMeere; D A Johnson; G L Amidon
Journal:  J Theor Biol       Date:  1988-03-07       Impact factor: 2.691

8.  [Formation of L-3-acylamino-6,7-dihydroxy-hydrocoumarins from N-acyl-3-(3,4-dihydroxyphenyl)-L-alanine].

Authors:  A Kaiser; W Koch; M Scheer; U Wölcke
Journal:  Helv Chim Acta       Date:  1970       Impact factor: 2.164

9.  Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa.

Authors:  M R Dobrinska; W Kukovetz; E Beubler; H L Leidy; H J Gomez; J Demetriades; J A Bolognese
Journal:  J Pharmacokinet Biopharm       Date:  1982-12

10.  Release of dipeptide hydrolase activities from rat small intestine perfused in vitro and in vivo.

Authors:  M L Gardner; J A Plumb
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

View more
  13 in total

Review 1.  Intestinal peptide transport systems and oral drug availability.

Authors:  C Y Yang; A H Dantzig; C Pidgeon
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells.

Authors:  C P Hsu; E Walter; H P Merkle; B Rothen-Rutishauser; H Wunderli-Allenspach; J M Hilfinger; G L Amidon
Journal:  AAPS PharmSci       Date:  1999

Review 3.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

4.  Molecular interactions between dipeptides, drugs and the human intestinal H+ -oligopeptide cotransporter hPEPT1.

Authors:  Monica Sala-Rabanal; Donald D F Loo; Bruce A Hirayama; Eric Turk; Ernest M Wright
Journal:  J Physiol       Date:  2006-04-20       Impact factor: 5.182

5.  Transport characteristics of L-carnosine and the anticancer derivative 4-toluenesulfonylureido-carnosine in a human epithelial cell line.

Authors:  Carsten Uhd Nielsen; Claudiu T Supuran; Andrea Scozzafava; Sven Frokjaer; Bente Steffansen; Birger Brodin
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

6.  Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2).

Authors:  M Hu; R T Borchardt
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

7.  Metabolism, uptake, and transepithelial transport of the diastereomers of Val-Val in the human intestinal cell line, Caco-2.

Authors:  K Tamura; P K Bhatnagar; J S Takata; C P Lee; P L Smith; R T Borchardt
Journal:  Pharm Res       Date:  1996-08       Impact factor: 4.200

8.  Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.

Authors:  Chun-Li Wang; Yang-Bin Fan; Hsiao-Hwa Lu; Tung-Hu Tsai; Ming-Cheng Tsai; Hui-Po Wang
Journal:  J Biomed Sci       Date:  2010-09-06       Impact factor: 8.410

Review 9.  Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery.

Authors:  J P Bai; G L Amidon
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

10.  Structural requirements for the intestinal mucosal-cell peptide transporter: the need for N-terminal alpha-amino group.

Authors:  P F Bai; P Subramanian; H I Mosberg; G L Amidon
Journal:  Pharm Res       Date:  1991-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.